Sudeep Pharma Limited — PPTs, 04-08-2026: Investor Presentation

Here's a summary of Sudeep Pharma's investor presentation:

**Business Performance:** Sudeep Pharma kicked off FY27 with a strong 27% YoY revenue growth, reaching Rs. 158.3 Cr. This broad-based performance was seen across its Pharma, Food & Nutrition, and Specialty Ingredients businesses, despite challenges like geopolitical issues and supply chain disruptions. The Specialty Ingredients segment showed robust growth, particularly in Premix and Encapsulation.

**Growth Drivers or Strategy:** The company is focused on two key strategic initiatives. First, its Greenfield expansion project is on track to boost manufacturing capabilities and broaden its product portfolio. Second, the Sudeep Advanced Materials (SAM) project, focusing on battery materials, is progressing well, with Phase 2 planning initiated due to strong customer interest. Integration efforts for the acquired NSS business in Europe are also progressing to drive efficiency.

**Recent Developments:** Regulatory approvals for the Greenfield expansion are moving forward, with customer qualification activities gaining momentum. Two additional MoUs were signed for the Sudeep Advanced Materials project.

**Key Financial Metrics:** Revenue from operations grew 27% YoY to Rs. 158.3 Cr. Profit After Tax (PAT) saw a 30% YoY increase to Rs. 40.6 Cr.

**Management Commentary / Outlook:** Management is confident about navigating the evolving global environment, citing a diversified portfolio, strong customer relationships, expanding global footprint, and ongoing growth initiatives. Investments in innovation and capacity are expected to drive sustainable long-term growth.